180 related articles for article (PubMed ID: 20732647)
1. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Novel targets in bone and cartilage.
Beyer C; Schett G
Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):489-96. PubMed ID: 20732647
[TBL] [Abstract][Full Text] [Related]
2. The role of Wnt proteins in arthritis.
Schett G; Zwerina J; David JP
Nat Clin Pract Rheumatol; 2008 Sep; 4(9):473-80. PubMed ID: 18756273
[TBL] [Abstract][Full Text] [Related]
3. Future therapeutic targets in osteoporosis.
Deal C
Curr Opin Rheumatol; 2009 Jul; 21(4):380-5. PubMed ID: 19461517
[TBL] [Abstract][Full Text] [Related]
4. A theoretical model for simulating effect of parathyroid hormone on bone metabolism at cellular level.
Wang Y; Qin QH; Kalyanasundaram S
Mol Cell Biomech; 2009 Jun; 6(2):101-12. PubMed ID: 19496258
[TBL] [Abstract][Full Text] [Related]
5. Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis.
Daoussis D; Andonopoulos AP; Liossis SN
Semin Arthritis Rheum; 2010 Apr; 39(5):369-83. PubMed ID: 19095294
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
7. Bone morphogenetic proteins in destructive and remodeling arthritis.
Lories RJ; Luyten FP
Arthritis Res Ther; 2007; 9(2):207. PubMed ID: 17381828
[TBL] [Abstract][Full Text] [Related]
8. Dynamic activation of bone morphogenetic protein signaling in collagen-induced arthritis supports their role in joint homeostasis and disease.
Daans M; Lories RJ; Luyten FP
Arthritis Res Ther; 2008; 10(5):R115. PubMed ID: 18816401
[TBL] [Abstract][Full Text] [Related]
9. Erosive arthritis.
Schett G
Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S2. PubMed ID: 17634141
[TBL] [Abstract][Full Text] [Related]
10. R-spondin 1 protects against inflammatory bone damage during murine arthritis by modulating the Wnt pathway.
Krönke G; Uderhardt S; Kim KA; Stock M; Scholtysek C; Zaiss MM; Surmann-Schmitt C; Luther J; Katzenbeisser J; David JP; Abdollahi-Roodsaz S; Tran K; Bright JM; Binnerts ME; Akhmetshina A; Böhm C; Distler JH; Joosten LA; Schett G; Abo A
Arthritis Rheum; 2010 Aug; 62(8):2303-12. PubMed ID: 20506554
[TBL] [Abstract][Full Text] [Related]
11. Fcgamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation.
van Lent PL; Grevers L; Lubberts E; de Vries TJ; Nabbe KC; Verbeek S; Oppers B; Sloetjes A; Blom AB; van den Berg WB
Arthritis Rheum; 2006 Dec; 54(12):3868-77. PubMed ID: 17133594
[TBL] [Abstract][Full Text] [Related]
12. The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?
Karsdal MA; Bay-Jensen AC; Lories RJ; Abramson S; Spector T; Pastoureau P; Christiansen C; Attur M; Henriksen K; Goldring SR; Kraus V
Ann Rheum Dis; 2014 Feb; 73(2):336-48. PubMed ID: 24285494
[TBL] [Abstract][Full Text] [Related]
13. Changes of cartilage and bone markers after intra-articular glucocorticoid treatment with and without postinjection rest in patients with rheumatoid arthritis.
Weitoft T; Larsson A; Saxne T; Rönnblom L
Ann Rheum Dis; 2005 Dec; 64(12):1750-3. PubMed ID: 15843449
[TBL] [Abstract][Full Text] [Related]
14. Role of RANKL in bone diseases.
Anandarajah AP
Trends Endocrinol Metab; 2009 Mar; 20(2):88-94. PubMed ID: 19185505
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
[TBL] [Abstract][Full Text] [Related]
16. Bone-cartilage interface crosstalk in osteoarthritis: potential pathways and future therapeutic strategies.
Yuan XL; Meng HY; Wang YC; Peng J; Guo QY; Wang AY; Lu SB
Osteoarthritis Cartilage; 2014 Aug; 22(8):1077-89. PubMed ID: 24928319
[TBL] [Abstract][Full Text] [Related]
17. Rheumatic diseases: the effects of inflammation on bone.
Walsh NC; Crotti TN; Goldring SR; Gravallese EM
Immunol Rev; 2005 Dec; 208():228-51. PubMed ID: 16313352
[TBL] [Abstract][Full Text] [Related]
18. Emerging targets of biologic therapies for rheumatoid arthritis.
Tarner IH; Müller-Ladner U; Gay S
Nat Clin Pract Rheumatol; 2007 Jun; 3(6):336-45. PubMed ID: 17538565
[TBL] [Abstract][Full Text] [Related]
19. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
20. Bone morphogenetic protein signaling in joint homeostasis and disease.
Lories RJ; Luyten FP
Cytokine Growth Factor Rev; 2005 Jun; 16(3):287-98. PubMed ID: 15993360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
